GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NAGE · Jun 30, 2023

Niagen Bioscience, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-23-028551General Corporate
Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

16.14% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

21.46% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

58.91% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

60.80% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-11.40% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

6.72% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.51% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible
Jun 30, 20220/6 normalizedLevel 3Sep 30, 20220/6 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20246/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20257/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Increased
Previous
12.38%
Current
16.14%
Delta
3.76%
Inventory Pressure Increased
Previous
52.79%
Current
58.91%
Delta
6.12%
Margin Increased
Previous
59.93%
Current
60.80%
Delta
0.87%
Profitability Decreased
Previous
-8.72%
Current
-11.40%
Delta
-2.67%
R And D Intensity Increased
Previous
5.29%
Current
6.72%
Delta
1.43%
Sbc Intensity Increased
Previous
5.64%
Current
6.51%
Delta
0.87%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · NAGE Fundamental State →Has State · Niagen Bioscience, Inc. →Transitioned To · NAGE Fundamental State →Transitioned To · NAGE CASH_GENERATION_INCREASED →Transitioned To · NAGE INVENTORY_PRESSURE_INCREASED →Transitioned To · NAGE MARGIN_INCREASED →Transitioned To · NAGE PROFITABILITY_DECREASED →Transitioned To · NAGE R_AND_D_INTENSITY_INCREASED →Transitioned To · NAGE SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.